No Data
Senseonics Stock Down Despite New FDA Approval for Eversense 365
BTIG Maintains Senseonics(SENS.US) With Hold Rating
BTIG analyst Marie Thibault maintains $Senseonics(SENS.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 34.7% and a total average return of -1.5% over the past
Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years and Older.
FDA Clearance Announcement Sends Small Cap Soaring
Senseonics Announces First CGM
Express News | Senseonics Holdings Inc - Launch Expected Early in Q4 of 2024